Intended Use
Comprehensive panel plus (DNA & RNA, 501 genes), NGS provides a comprehensive genomic profiling solution by analysis of various single-gene variants, such as SNVs, indels, fusions, splice variants, and CNV, including both copy number gains and losses across 500+ genes. It detects complex biomarkers associated with TMB and MSI.
Specimen Required
FFPE tumor tissue
Patient Preparation
- Sample Collection: FFPE tumor tissue
- Specimen Preparation: Formalin fix (10 percent neutral buffered formalin) and paraffin embedded tissue. Protect from excessive heat. Tissue block will be returned after testing. Transport tissue block or 5 unstained 5-micron slides.
- Storage/Transport Temperature: Room temperature. Ship in cooled container during summer months.
- Unacceptable Conditions
- Less than 25 percent tumor.
- Specimens fixed in any fixative other than 10 percent neutral buffered formalin.
- Bone specimens submitted in non-EDTA decalcifier.
- Remarks: Include surgical pathology report. If multiple specimens are sent to CMDL without a request for pathologist block/slide selection or individual orders, they will be held until clarification is provided.
- Stability: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology
Massively Parallel Sequencing: Comprehensive panel plus (DNA & RNA, 501 genes), NGS is a next-generation sequencing (NGS) that analyses 501 important cancer-related genes, detecting a wide range of genetic changes.
Sample Received to Report Turnaround Time (TAT)
Twice in a week (Scheduled Test)
Reference Interval
–
Interpretive Data
Refer to report.
Resources
- Additional Technical Information
- Test Request Form
Sample Reports
- Enhanced Report
- See report